Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v18-FR Version v2-FR
Language French French
Date Updated 2022-12-07 2022-03-04
Drug Identification Number 02483327 02483327
Brand name ACTEMRA ACTEMRA
Common or Proper name ACTEMRA ACTEMRA
Company Name HOFFMANN-LA ROCHE LIMITED HOFFMANN-LA ROCHE LIMITED
Ingredients TOCILIZUMAB TOCILIZUMAB
Strength(s) 162MG 162MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS SUBCUTANEOUS
Packaging size Autoinjector Autoinjector
ATC code L04AC L04AC
ATC description IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2022-04-30 2022-03-31
Actual start date 2022-05-09
Estimated end date Unknown
Actual end date 2022-12-06
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Due to ongoing global product constraint, orders containing this product will be fulfilled based on current supply.
Health Canada comments